ARCHIVES

Bosutinib Vs. Imatinib Study Didn’t Meet Primary Endpoint

This article is from The Cancer Letter archive.

Vol. 33 No. 12 | December 31, 2010

Download PDF Visit The Full Archive

Related Articles

Toxicology Program Board To Review Nine Substances.

January 14, 2000

Missouri Center Director Search Narrowed To Vincent, Wiernik

September 10, 1982

In Brief: Golomb, Weinstein Head ASCO, AACR; Abeloff, Moses Presidents Elect; Sackett Heads AUR

June 1, 1990

‘Approval to Apply’ For Proton Facility Upgrade Denied

February 24, 1989

In Brief: Painter Is AMA President-Elect; FDA Approves Taxol; Protocol Enrolls 150-200 A Month

August 14, 1992

Conversation with The Cancer Letter: Statistician Lori Dodd Saw Research Question In the Midst of 2007 ODAC Debate Over Avastin

July 27, 2012